Purple Biotech Ltd.

0.77 USD
+0.01 (+1.38%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Purple Biotech Ltd. stock is up 22.22% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 February’s closed higher than January.

About Purple Biotech Ltd.

Purple Biotech Ltd. focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors. NT219, a small molecule that targets insulin receptor substrate substrate substrate 1 and 2, and signal transducer and activator of transcription, is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors.